Search fresh public links, source activity, and ready-to-use post angles for Drug Development.
Fresh curated links around Drug development are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Delve into the hidden innovation system of drug repurposing. When patents expire and commercial value fades, a new wave of research starts. The post The hidden innovation system be...
ProBio is building flexible platforms for multispecific antibodies, ADCs, and other advanced therapeutic approaches. The post From Discovery to Development in Emerging Modalities a...
Tighter capital, higher expectations and evolving regulatory frameworks are reshaping drug development strategy. Parexel leaders explain how companies are adapting.
In early discovery, researchers use high-throughput screening (HTS) to identify active compounds in a biologically relevant context. During lead characterization and validation, th...
AI will continue changing how small molecules are discovered, but the candidates that generate the most interest in silico still have to succeed under real development conditions....
For sterile injectables, key early decisions can have a significant impact on the products’ development.
Macrocycles, de novo antibodies, and mRNA therapies are expanding the drug discovery toolbox for unmet patient needs. The post Novel Therapeutic Modalities Target the Undruggable a...
By Charles D. Snow & Kalie E. Richardson —
TUCSON, Ariz., and AMSTERDAM — May 19, 2026 — In a transformative step for drug development and regulatory science, the Critical Path Institute (C-Path) has officially launched the...
As researchers work to develop new cancer treatments, one of the biggest challenges is identifying promising drug candidates quickly and efficiently. Now, researchers at Purdue Uni...
Explore how FDA Breakthrough Therapy and RMAT designations can create opportunities for oncology programs when backed by the right development strategy.
Many startups and established companies focused on drug testing on human data in preclinical studies have been boosted by FDA’s move away from reliance on animal testing towards or...
Discover how precision oncology companies are using AI and patient-relevant biology to reduce clinical trial failures in cancer. The post Rethinking precision oncology drug develop...
In a quest to provide more relevant translational data, traditional in vivo models join forces with new approach methodologies. The post Next Generation Biopharma Innovation appear...
We have spoken with Reason from Repair Biotechnologies about his company’s lead candidate, REP-0004, a drug targeting the liver to reduce excess intracellular free cholesterol. The...
The in-depth, constantly-changing birds-eye view of disease that computational models provide is an essential next step in linking our ever-expanding clinical knowledge and data wi...
China’s Order 818 signals the country’s intent to accelerate local innovation and standardize the drug development environment, thereby becoming a more important player in advanced...
Clinical trials in China are getting attention at an international oncology gathering in Chicago. China’s surging biotechnology industry is fueling alarm that U.S. dominance in the...
A series of newly planned reforms are designed to entice companies to start early trials in the U.S. rather than overseas.
The partnership’s first phase will see a review of the current medicines landscape conducted to identify opportunities for innovation. This information will be used to find systemi...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.